SENTIA: an intensive medicines monitoring programme for proactive safety surveillance of neuroleptic treatment in children and adolescents

被引：0
|
作者：
Palanca Maresca, Inmaculada [1 ]
Ruiz-Antoran, Belen [2 ]
Olza-Fernandez, Ibone [1 ]
Siles, Ana [3 ]
Villagra, Sandra [3 ]
Fernandez Rivas, Aranzazu [4 ]
Garcia Vega, Juan Manuel [1 ]
Centeno, Gustavo [2 ]
Roman, Enriqueta [5 ]
Avendano-Sola, Cristina [2 ]
机构：
[1] Univ Puerta de Hierro, Majadahonda Hosp, Child & Adolescent Psychiat Unit, Madrid, Spain
[2] Univ Puerta de Hierro, Majadahonda Hosp, Dept Clin Pharmacol, Madrid, Spain
[3] Univ Puerta de Hierro, Majadahonda Hosp, Paediat Cardiol Unit, Madrid, Spain
[4] Basurto Hosp, Child & Adolescent Psychiat Unit, Bilbao, Spain
[5] Univ Puerta de Hierro, Majadahonda Hosp, Paediat Serv, Madrid, Spain
来源：
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY | 2013年 / 22卷
关键词：
Antipsychotic; adverse effects; pharmacovigilance registry; paediatric populations;
D O I：
暂无
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
PS-046
引用
收藏
页码：S230 / S231
页数：2
相关论文
共 50 条
  • [1] SENTIA. AN INTENSIVE MEDICINES MONITORING PROGRAMME FOR PROACTIVE SAFETY SURVEILLANCE OF NEUROLEPTIC TREATMENT IN CHILDREN AND ADOLESCENTS. RESULTS FROM TWO YEARS FOLLOW-UP STUDY
    Ruiz, B.
    Palanca, I
    Centeno, G.
    Siles, A.
    Salcedo, I
    Garcia Vega, J. M.
    Villagra, S.
    Roman, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 7 - 7
  • [2] The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance
    Coulter, DM
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2000, 9 (04) : 273 - 280
  • [3] A Pilot Intensive Safety Surveillance Scheme for Medicines Under Additional Monitoring Used in the Treatment of Cancer
    Penedones, A.
    Mendes, D.
    Rigueiro, G.
    Batel-Marques, F.
    Alves, C.
    Sousa, R.
    Sousa, G.
    DRUG SAFETY, 2019, 42 (10) : 1233 - 1233
  • [4] SENTIA: ONLINE SPANISH SAFETY REGISTRY FOR NEUROLEPTIC TREATMENT IN CHILDREN AND ADOLESCENTS. RESULTS FROM 1 YEAR FOLLOW-UP STUDY
    Ruiz-Antoran, B.
    Palanca, I
    Centeno, G.
    Cabrera, L.
    Garcia, J. M.
    Avendano, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 23 - 23
  • [5] The New Zealand Intensive Medicines Monitoring Programme
    Coulter, DM
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 1998, 7 (02) : 79 - 90
  • [6] Intensive safety surveillance of anticancer medicines subject to additional monitoring: A pilot study
    Mendes, Diogo
    Rigueiro, Graca
    Silva, Rui Sousa
    Penedones, Ana
    Alves, Carlos
    Sousa, Gabriela
    Marques, Francisco Batel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 198 - 198
  • [7] SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics
    Palanca-Maresca, Inmaculada
    Ruiz-Antoran, Belen
    Centeno-Soto, Gustavo
    Jimenez-Fernandez, Sara
    Garcia-Murillo, Lourdes
    Siles, Ana
    Villagra, Sandra
    Blasco-Fontecilla, Hilario
    Iruela-Cuadrado, Luis
    Roman-Riechman, Enriqueta
    Avendano-Sola, Cristina
    Correll, Christoph U.
    SPRINGERPLUS, 2014, 3
  • [8] Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme
    Coulter, DM
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (07) : 663 - 667
  • [9] SENTIA: Spanish Online Adverse Effect Registry for safe antipsychotic treatment in children and adolescents
    Maresca, Palanca Inmaculada
    Antoran, Ruiz Belen
    Jimenez, Sara
    Olza, Ibone
    Sancho, Arancha
    Sancho, Arancha
    Cabrera, Lourdes
    Valencia, Alfredo
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2011, 20 (01) : S205 - S205
  • [10] Mortality among users of formoterol in the New Zealand intensive medicines monitoring programme
    Castellsague, J
    Ashton, J
    Pethica, D
    Coulter, DM
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A136 - A136
12345